hPSCs and their differentiated forms have been expected to dramatically impact the life science industry. However, there were no real commercially viable products for the industry and consumers.
Elixirgen Scientific’s Chief Scientific Advisor’s research at the National Institute on Aging (NIA, NIH) and Keio University identified systematic approaches to establish hPSC differentiation protocols.
Based on the approaches, transcription factor-based differentiation technologies have been developed to switch hPSCs into differentiation mode by activating key genes. This approach does not modify cells’ genetic profile.
The company was founded by Elixirgen, LLC in 2016 to commercialize fast human pluripotent stem cell (hPSC) differentiation technologies. They started providing one-week human pluripotent stem cell differentiation reagent kits and services worldwide in February 2017.
CEO: Bumpei Noda
President: Akihiro Ko
CSO: Minoru S.H. Ko, M.D., Ph.D
One-week human pluripotent stem cell differentiation reagent kits and services worldwide in February 2017.